December 1, 2022

The Current State of Music NFTs

NFTS are Shaking Up the Music Industry

NFTS are Shaking Up the Music Industry

There was a time when all you could purchase with non-fungible tokens (NFTs) were those mopey monkeys that people inexplicitly bought for ridiculous amounts of money. Today, NFTs can do so much more than buy Bored Apes – especially for the music industry.

As you probably know, an NFT is a digital asset that represents real-world objects, such as art, in-game items, and music. Like other types of cryptocurrency (crypto), NFTs are bought and sold online through a digital database that creates a permanent, transparent record of the transaction. An NFT functions somewhat like a zip file with artwork on the front and nifty assets, such as music, tickets or videos, on the inside.

NFTs are still in their infancy, but their potential is becoming clear. Some of music’s heaviest hitters, such as Linkin Park’s Mike Shinoda and Kings of Leon, have already adopted NFT technology to reach more fans. The musician known as Grimes launched an NFT campaign that combined artwork and videos set to music, and she raked in a cool $6 million – which is the equivalent of a couple of billion Spotify streams. These fat stacks allow artists to compete with record labels while retaining ownership of their masters and their work.

New Opportunities for Partnerships

NFTs also create opportunities for collaboration. Intercept Music recently partnered with Method Man to create a new platform for independent labels and music artists, intending to create a digital distribution platform that empowers both artists and labels by giving them access to hundreds of digital stores and major streaming outlets. Intercept Music has partnerships with some of the biggest music marketplaces and distribution services, including Nifter.

These collaborations may be a lifesaver for artists, who suffer from a broken music industry that splits profits between the big dogs and leaves the musicians with pennies on the dollar. NFTs offer a more sustainable and equitable model for artists by creating a system that gives musicians more control over their work, and in the end, puts more money in their pockets.

NFTs Enhance the Connection between Creators and Fans

NFTs also work out for the fans, in that they create an opportunity for artists to connect with their base in a more personal (and profitable) way. Users often have a passive relationship with music – they listen to their favorite songs without any interaction with the artists that created them. Until NFTs came along, the only way for fans to gain greater ownership of their relationship with the artists was to buy VIP tickets with meet-and-greet or to purchase merchandise.

NFTs foster a more dynamic relationship by giving listeners an opportunity to engage and participate with the artist in ways that go well beyond the merch table. Fans can purchase limited edition or one-of-a-kind albums, buy physical or digital merchandise, or even interact with their favorite artists online.

But what about the “crypto winter?”

Bitcoin and other types of cryptocurrency have recently experienced a downturn, dubbed by many as “crypto winter.” Prices dropped and remained low, creating a bear market that has chilled interest in NFTs for some investors. Crypto winter has not frozen out many big players, though.

“I feel like every great industry has a downfall,” said Snoop Dogg when asked if he was concerned about the current crypto crash, for example. “There’s been a depression in every industry you can look at: alcohol, tobacco, clothing, food; every industry you can imagine.”

The music mogul isn’t alone. Billionaire Mark Cuban compared the crypto crash to the lull the internet experienced when the dotcom bubble burst. Cuban even went so far as to say that the NFT space was oversaturated with wanna-be investors, and that cyber winter weeded out all the people who weren’t supposed to be there. Snoop, Cuban and other NFT enthusiasts are still hot for the digital currency.

How do you make an NFT?

Making an NFT is easier than you probably realize. The first step, of course, is to find out as much you can so that you go into the venture wisely. Learn about gas fees, for example, which is the fee you pay to execute any transaction on the blockchain. The more you know before you dive in, the more successful your NFT venture will likely be.

Pick an asset

You can turn almost any digital file into an NFT, as long as you are the sole owner and nobody else has intellectual property rights.

  • Music
  • Video clips
  • Pictures
  • Artwork, such as drawings or paintings
  • Tweets and other online content
  • GIFs and memes

Start simple with an audio clip, video, or image, as these are the most commonly accepted formats in various marketplaces.

Choose a blockchain

A blockchain is a type of public ledger that records transactions made in bitcoin or other types of cryptocurrency. Ethereum and Solana are the top blockchains choices for NFT creators.

Choose a marketplace

Marketplaces are the online platforms in which users store, display, buy, sell, trade, and mint NFTs. NIFTER, Nifty Gateway, OpenSea and Rarible are among the most popular marketplaces.

Set up a digital wallet and add cryptocurrency

You’ll store your cryptocurrency in your digital wallet. MetaMask, Coinbase Wallet, and Alpha Wallet are among the most popular. Be sure to choose a digital wallet accepted by your marketplace of choice.

Upload your file

Upload and create a file that contains your NFT. Once you gain experience in uploading your NFTs, you can mint (publish) them directly on the blockchain. Newbies should use the minting tools provided by their marketplace. Connect your digital wallet to the marketplace to establish a payment system. Once your digital wallet is connected, the marketplace will publish your NFT. Your marketplace will assign unique metadata to your asset and record it on the blockchain. If you’d like, you can create extra value for your NFT by adding a smart contract that lays out the terms and conditions of the transaction.

Next, sit back and rake in the money. You can list your NFT at a fixed price or sell it auction-style to the highest bidder. While many NFTs never sell or earn very little money, it is entirely possibly that you will be the next music NFT to rise above and find success.

ABOUT FRANK MAGLIOCHETTI

Frank Magliochetti owes his professional success to his expertise in two areas: medicine and finance. After obtaining a BS in pharmacy from Northeastern University, he stayed on to enroll in the Masters of Toxicology program. He later specialized in corporate finance, receiving an MBA from The Sawyer School of Business at Suffolk University. His educational background includes completion of the Advanced Management Program at Harvard Business School and the General Management Program at Stanford Business School. Frank Magliochetti has held senior positions at Baxter International, Kontron Instruments, Haemonetics Corporation, and Sandoz. Since 2000, he has been a managing partner at Parcae Capital, where he focuses on financial restructuring and interim management services for companies in the healthcare, media, and alternative energy industries. Last year, he was appointed chairman of the board at Grace Health Technology, a company providing an enterprise solution for the laboratory environment.

Frank is the CEO of ClickStream, ClickStream’s business operations are focused on the development and implementation of apps that disrupt such as WinQuik™, a free to play synchronized mobile app and digital gaming platform. The platform is designed to enable WinQuik™ users to have fun, interact and compete against each other in order to win real money and prizes. Twitter at @ClickstreamC  @WinQuikAppNifter™, a music NFT marketplace that allows recording artists to create and sell limited edition authenticated NFTs, and their ever expanding foreign language exchange social learning app  @HeyPalApp. ClickStream is also entering the E-Learning market with Joey’s Animal Kingdom- please visit them online at wowee.world

Frank was appointed Chairman and Chief Executive Officer at Designer Genomics International, Inc. The Company has accumulated a growing body of evidence that highlights a link between alterations in the immune and inflammatory systems and the development of chronic human disease. The Company is visionary and has established itself as a leader in the field of inflammatory and immune genetic DNA and RNA biomarkers that play a causative role in debilitating conditions, such as atherosclerosis/heart disease, diabetes, arthritis, inflammatory bowel disease, post-traumatic stress disorders (PTSD) and cancer.
A proprietary state-of-the art data mining bioinformatics program, called ‘cluster analysis’ will be used to measure disease development susceptibility with potential for earlier diagnosis and intervention. The company is developing a healthcare program based on its proprietary genetic panels that will allow people to be their own healthcare advocate and take an active role in their health status as well as longevity.
Frank is a highly sought after multifaceted senior C level executive.

NFT News Update 2022: Using Today’s NFTs as a Marketing Tool

NFT’s as a Marketing Tool

Non-fungible tokens (NFTs) are coming into their own, now becoming an important part of the digital economy. The original goal of NFTs was to develop a monetary system that confirms assets – usually artwork – as individually unique, traceable and verifiable. These confirmations can be applied to anything digital, making the assets basically un-hackable and uncopiable.

Like most disruptive technologies, the journey to widespread acceptance and use has been along a twisted, and sometimes bumpy road. Largely discounted at their creation in 2014, NFTs surged in 2021, stabilized in early 2022, and faltered a bit mid-year. During their development, NFTs gained a reputation as being difficult to use. Some NFTs even turned out to be digital snake oil.

Even as many people struggle to understand NFTs, or are reluctant to jump on board, demand for NFTs has surged. In fact, NFTs topped $17 billion in 2021 and are poised to surpass $147 billion by 2026. As of March 2022, there were more NFTs than public websites. NFT marketplaces like Nifter, recently launched by ClickStream, are largely responsible for this growth because this new generation is easy to use, reliable, and secure.

Tomorrow’s NFT – A Powerful Marketing Tool Like No Other

As NFTs have grown, they have evolved past being merely a way to sell music or artwork. Once dismissed as a fad, NFTs have tremendous staying power and are now entering the mainstream. Today, these digital tokens are now in use as a sophisticated approach to marketing. Major brands, such as such as Budweiser, McDonald’s and Adidas, have introduced their own NFTs. A number of celebrities, including Tom Brady and Snoop Dogg, have either purchased NFT collections or launched their own.

Selling NFTs allow companies to lead customers on a journey through different price points and offer rewards based on the clients’ level of engagement. They are also a way for entrepreneurs to identify their strongest supporters.

Entrepreneur, author, speaker and internet personality Gary Vaynerchuk created Veefriends to build a community around his creative and business interests using NFT technology. His tokens recently pulled double duty during the multi-day superconference, VeeCon 2022, where holders of a VeeFriends series 1 NFT used the digital currency to get in the front door and gain access to original artwork and surprise gifts. Using NFT technology also allows Vaynerchuk to distinguish between superfans and casual conference-goers. Vayner’s VaynerMedia, a global creative and media agency, also recently partnered with Johnnie Walker to offer loyal customers a special and limited edition of blue label whiskey.

Vaynerchuk is far from the only entrepreneur and business leader to use NFTs to grow support for their products. Prada recently launched 100 Ethereum NFTs to coincide with the release of its latest Timecapsule apparel from Prada’s latest partnership with Cassius Hirst, son of English artist, entrepreneur, and art collector Damien Hirst. Buyers will receive an NFT along with their purchase.

The project, known the Timecapsule NFT Collection, is a monthly online event in which shoppers can access both a physical product and a gifted NFT. Each Timecapsule item bears a unique serial number and in packaging exclusive to its contents. The brand’s initial offering is Prada x Cassius Hirst black or white shirts that come with a corresponding GIF of a black or white pill capsule. The NFTs validate the transaction by referring to the serial number of the drop and by assigning a number to each individual shirt.

Big businesses are not the only ones taking advantage of the power of the digital currency – individuals are also making the most of the NFT communities. NFTs helped Chanel Lee bring her memes Tasty Toastys to market, for example. Lee introduced her randomly-generated bread cartoon in November 2021, before she had built up an international network substantial enough to attract attention to her cute and simple designs. After reworking and relaunching the collection in January 2022, Lee began holding gatherings on Twitter Spaces in which Tasty Toastys NFT holders can chat with each other in audio conversations; she also created an exclusive Discord server for NFT holders who prefer to type. Tasty Toastys also host events in the metaverse, such as the Decentraland party in which community members can wear a Tasty Toastys backpack while dancing to a live DJ, all as their NFTs hovers over their shoulders.

It’s hard to tell where NFTs will be in a year from now, but one thing is clear – NFTs will continue revolutionizing how we market, track purchases, and talk about art and all other commodities, digital and otherwise.

ABOUT FRANK MAGLIOCHETTI

Frank Magliochetti owes his professional success to his expertise in two areas: medicine and finance. After obtaining a BS in pharmacy from Northeastern University, he stayed on to enroll in the Masters of Toxicology program. He later specialized in corporate finance, receiving an MBA from The Sawyer School of Business at Suffolk University. His educational background includes completion of the Advanced Management Program at Harvard Business School and the General Management Program at Stanford Business School. Frank Magliochetti has held senior positions at Baxter International, Kontron Instruments, Haemonetics Corporation, and Sandoz. Since 2000, he has been a managing partner at Parcae Capital, where he focuses on financial restructuring and interim management services for companies in the healthcare, media, and alternative energy industries. Last year, he was appointed chairman of the board at Grace Health Technology, a company providing an enterprise solution for the laboratory environment.

Frank is the CEO of ClickStream, ClickStream’s business operations are focused on the development and implementation of apps that disrupt such as WinQuik™, a free to play synchronized mobile app and digital gaming platform. The platform is designed to enable WinQuik™ users to have fun, interact and compete against each other in order to win real money and prizes. Twitter at @ClickstreamC @WinQuikApp, Nifter™, a music NFT marketplace that allows recording artists to create and sell limited edition authenticated NFTs, and their ever expanding foreign language exchange social learning app @HeyPalApp. ClickStream is also entering the E-Learning market with Joey’s Animal Kingdom- please visit them online at wowee.world

Frank was appointed Chairman and Chief Executive Officer at Designer Genomics International, Inc. The Company has accumulated a growing body of evidence that highlights a link between alterations in the immune and inflammatory systems and the development of chronic human disease. The Company is visionary and has established itself as a leader in the field of inflammatory and immune genetic DNA and RNA biomarkers that play a causative role in debilitating conditions, such as atherosclerosis/heart disease, diabetes, arthritis, inflammatory bowel disease, post-traumatic stress disorders (PTSD) and cancer.
A proprietary state-of-the art data mining bioinformatics program, called ‘cluster analysis’ will be used to measure disease development susceptibility with potential for earlier diagnosis and intervention. The company is developing a healthcare program based on its proprietary genetic panels that will allow people to be their own healthcare advocate and take an active role in their health status as well as longevity.
Frank is a highly sought after multifaceted senior C level executive.

This image has an empty alt attribute; its file name is frankmagliochetti_FrankMagliochettiNews.jpg

Mr. Frank Magliochetti MBA
Managing Partner Parcae Capital
www.parcaecapitalcorp.com
www.frankmagliochetti.com

ClickStream CEO Frank Magliochetti Talks about Disrupting Conventional Industries Through Apps

ClickStream CEO Talks Disruption Through Apps

CLICKSTREAM CEO FRANK MAGLIOCHETTI TALKS DISRUPTING CONVENTIONAL INDUSTRIES THROUGH APPS, EXPLODING NFT TECH, AND WHY CLIS IS A SMART INVESTMENT TODAY

In an incredibly thorough and and candid interview Hazel Saunders of the Ritz Herald talks with Frank M<agliochetti about all things ClickStream!

Here is the Interview: for the original source please head to The Ritz Herald.

There are no businesses with greater potential today than those positioned to dominate booming digital economies. One company that knows that more than anyone is ClickStream, a rapidly expanding business that is on a mission to disrupt conventional industries by way of game-changing mobile apps. ClickStream is traded on the stock market as CLIS.

These app subsidiaries span a multitude of industries: from gaming and language learning to investing early on tech which facilitates the exploding NFT industry. But though the genre they cover vary, all have one thing in common: each is revolutionizing its field with trailblazing tech – and already reaping the rewards.

The man behind the innovation is CEO and founder, Frank Magliochetti, who has led the business since 2019. Here, we sit down with the CEO as he reveals the surprisingly simple secret to the company’s success, what makes ClickStream’s apps unique, and why the business is such a smart investment option today…

What does a typical day look like for you as the CEO of ClickStream?

It’s about focusing on priorities and not on the noise which creeps into your day. My typical day involves being focused on the initiatives which drive enterprise value, which is critical when dealing with startups like CLIS.

Keeping team members aligned on our quarterly objectives is also vital for our success. Many distractions can enter into your day, so discipline to remain focused on critical success factors is always our daily goal.

What makes ClickStream apps like HeyPal, WinQuick, and Nifter so different from the competition?

Let me walk you through each! HeyPal is different from the competition in one simple way: users learn languages the most natural and human way possible – with other people! Studies show that social interaction is a key component, and arguably the most vital aspect of language learning.

HeyPal makes it easy to find new penpals to learn a language with through direct messaging, a special teacher/student matching algorithm, and a common social feed – all of which can be instantly translated from native to learning language instantly, and vice versa.

All the features of HeyPal are built around creating human connections and practicing new languages in context. While traditional learning methodologies like flashcards, rote memorization, and lessons are important to language learning, many platforms lack social interaction and the “live” components. This is where real practice occurs and why many who study new languages never actually apply those learnings, and often lose their progress.

Beyond the base human interactions, many language learners find that special person and a keen interest, offering more motivation to “impress” their counterparts, and providing the missing, but vital, accountability factor.

Then we have WinQuik. This is one of only two platforms in the market that offers live-hosted trivia games for Android and iOS. Trivia HQ is the other. WinQuik’s live games are different – and better than – HQ because of our unique timing mechanism. Our technology allows users to be timed as they answer live trivia questions. The ones who answer the most questions correctly in the fastest amount of time reach the top of WinQuik’s leaderboard. WinQuik’s payouts are larger because the app can isolate the top fastest users, whereas HQ splits the pot amongst the thousands who got all 10 questions correct that day leading to diluted payouts.

Also, WinQuik has layered security measures to ensure bots, duplicate accounts, and unverified users do not play and do not end up on the leaderboard. Other trivia apps like HQ seem to be more passive on such security efforts.

Plus, unlike HQ, WinQuik offers four different game types that can be played 24/7 including a 1 vs. 1 challenge feature that allows users to play friends and family in trivia contests for coins that they “bet” against each other. Cash prizes are offered for users who complete the most amount of 1 vs. 1 challenge in a week.

Nifter is a unique NFT platform because of its niche appeal to music lovers. It is the first NFT marketplace to focus solely on songs being minted as NFTs. There is no other ‘noise’ on the platform such as dancing cats or artworks of French Bulldogs. Currently, other NFT marketplaces such as Nifty drop NFTs for collectibles that support the artist and their music, but aren’t the actual songs – album art, fan experiences, etc. ClickStream is working to partner with major record labels, music groups, producers, and recording artists to tap into the uncharted territory of song NFTs. Other platforms have shied away from minting the non-independent songs because of an unwillingness to work with the entities that own the music. Nifter’s business model is to partner with the music giants to create a brand extension for their artists.

Are your current apps large enough to sustain the company as a competitive investment in the major public markets?

Absolutely, or we would never have invested in them. The HeyPal segment exceeds 1 billion, and the NFT segment is at an embryonic stage. This segment is going to explode and we have a turnkey marketplace that can go horizontal in any segment. It is a transferable platform. The opportunity is enormous. Then, our children’s entertainment and education app, Joey’s Animal Kingdom, is in a segment that is growing by double digits, with the global segment is in the billions.

How are you capitalizing the company and will it be sustainable on the market? Is the company financing through debt or through equity and how will that affect shareholder value?

We finance our operations and growth through equity. Don’t lose sight: we are an OTC company in a startup situation in which we internally finance start-up projects. In other words, we are an incubator. Financing OTC enterprises is challenging and we have our niche in how we raise capital. To date, it has worked.

It is our intent for the successful companies in our asset portfolio that we will seek additional capital by externally funding them. An example of which could be uplisting one of our subsidiaries. This will provide enormous enterprise value CLIS.

Where do you see the company 5 years from now?

It is our goal to have 3 to 4 subsidiaries listed to Nasdaq and to have CLIS as a Nasdaq listed company.

Why should someone buy stock in your company?

It is our opinion that our stock is grossly undervalued at this time. Our subsidiary values are grossly undervalued. All OTC stocks are speculative for a host of reasons – and Sustainability and Growth Potential are key indicators of unrealized value. Compare the markets our subsidiaries are into the Sustainability and Growth Potential and you will c see we are clearly positioned for success. There is no guarantee, however, there’s no doubt about it that we are in explosive segments.

ABOUT FRANK MAGLIOCHETTI

Frank Magliochetti owes his professional success to his expertise in two areas: medicine and finance. After obtaining a BS in pharmacy from Northeastern University, he stayed on to enroll in the Masters of Toxicology program. He later specialized in corporate finance, receiving an MBA from The Sawyer School of Business at Suffolk University. His educational background includes completion of the Advanced Management Program at Harvard Business School and the General Management Program at Stanford Business School. Frank Magliochetti has held senior positions at Baxter International, Kontron Instruments, Haemonetics Corporation, and Sandoz. Since 2000, he has been a managing partner at Parcae Capital, where he focuses on financial restructuring and interim management services for companies in the healthcare, media, and alternative energy industries. Last year, he was appointed chairman of the board at Grace Health Technology, a company providing an enterprise solution for the laboratory environment.

Frank is the CEO of ClickStream, ClickStream’s business operations are focused on the development and implementation of apps that disrupt such as WinQuik™, a free to play synchronized mobile app and digital gaming platform. The platform is designed to enable WinQuik™ users to have fun, interact and compete against each other in order to win real money and prizes. Twitter at @ClickstreamC  @WinQuikAppNifter™, a music NFT marketplace that allows recording artists to create and sell limited edition authenticated NFTs, and their ever expanding foreign language exchange social learning app  @HeyPalApp. ClickStream is also entering the E-Learning market with Joey’s Animal Kingdom- please visit them online at wowee.world

Frank was appointed Chairman and Chief Executive Officer at Designer Genomics International, Inc. The Company has accumulated a growing body of evidence that highlights a link between alterations in the immune and inflammatory systems and the development of chronic human disease. The Company is visionary and has established itself as a leader in the field of inflammatory and immune genetic DNA and RNA biomarkers that play a causative role in debilitating conditions, such as atherosclerosis/heart disease, diabetes, arthritis, inflammatory bowel disease, post-traumatic stress disorders (PTSD) and cancer.
A proprietary state-of-the art data mining bioinformatics program, called ‘cluster analysis’ will be used to measure disease development susceptibility with potential for earlier diagnosis and intervention. The company is developing a healthcare program based on its proprietary genetic panels that will allow people to be their own healthcare advocate and take an active role in their health status as well as longevity.
Frank is a highly sought after multifaceted senior C level executive.

ABOUT CLICKSTREAM CORPORATION

ClickStream is a technology company focused on developing apps and digital platforms that disrupt conventional industries. The company is currently marketing and developing WinQuik™ , HeyPal™ , Nifter™ and Joey’s Animal Kingdom™ respectively. For more information, please visit them online at ClickStream.Technology and follow them on social media: Twitter at @ClickstreamC and Instagram at clickstreamcorp.

WinQuik™ is a free-to-play synchronized mobile app and digital gaming platform. The platform is designed to enable WinQuik™ users to have fun, interact and compete in order to win real money and prizes. For more information, please visit them online at winquik.com/ and follow them on social media: Twitter at @winquikapp and Instagram at winquiktrivia/.

HeyPal™, by way of ClickStream subsidiary Nebula Software Corp., is a language learning app that focuses on “language exchanging” between users around the world. For more information, please visit them online at heypalapp.com and follow them on social media: Twitter at @HeypalA and Instagram at heypalapp.

Nifter™, by way of ClickStream subsidiary Rebel Blockchain Inc., is a music NFT marketplace that allows artists to create, sell and discover unique music and sound NFTs on the Nifter™ marketplace. For more information, please visit them online at nifter.io and follow them on social media: Twitter at @Nifter7 and Instagram at nifter.io.

Joey’s Animal Kingdom™ is a children’s entertainment and education app that takes kids all around this amazing planet to see incredible animals and creatures. For more information about Joey’s Animal Kingdom™, please visit them online at wowee.world.

Smart Tech: Wearable Medical Devices

Smart Tech:  Wearable Medical Devices 2017 – 2020

Smart technologies will continue to drive the ever-growing medical wearable device market in 2017 and well into the future.
The global medical wearable devices market topped $3.2 billion in revenue in 2015, according to Mordor Intelligence, which expects the market to surpass $7.9 billion in 2020 as the industry continues to grow at a healthy CAGR of 19.8 percent during that period.
wearablemedicaldevices_frank-magliochetti-reportWearable medical devices, known simply as “wearables,” are small pieces of equipment featuring sensors that attach to the body. These sensors detect and monitor changes in specific body signatures produced by various body systems and organs. Early wearable technology allowed consumers to monitor vital signs. Today’s wearables allow users to monitor food intake, activity, and sleep levels. Tomorrow’s devices may provide continuous monitoring of glucose levels, smart clothing for infants, and smart EKG necklaces for those with heart problems.
Wearables have the potential to fill a number of applications in remote patient monitoring, sports and fitness monitoring, and home healthcare. Simplified usage of these devices, coupled with the ability to synchronize with smartphones and tables, assisted growth in this segment.
Global Wearable Devices Market- Market Dynamics

There are immense potential socio-economics of wearable medical devices for multiple sectors. Fitness devices that encourage the users to exercise can significantly reduce healthcare costs, for example.

Investors are focusing on a wide variety of projects, ranging from downloadable apps to improving the size, cost and sensitivity of sensors.wearablemedicaldevices_frankmagliochettireport

Several factors propel the growth of the global wearable market. Technological innovation is perhaps the most important factor, as these advancements lead to the introduction of new products.
Diabetes and other chronic diseases are rising at a seemingly uncontrollable rate. Wearable devices will play an increasingly important role in helping doctors and patients manage chronic diseases.

Developers make wearable devices easier to use and simplify interpretation of the data collected. Simplicity encourages use.
Market penetration of smartphones, smart watches and other wearable devices will promote the use of wearable medical technology. These devices have already penetrated the market deeply, with the worldwide smart watch shipments reaching about 25 million in 2015.

Some factors, such as reimbursement issues and high device cost, will restrain the medical wearables market somewhat but the effect should be minimal, as demand should remain high.
Several companies are already exploiting the growing interest in medical wearable technology by creating affordable products that offer high value to users and their healthcare partners.

Some of the key players already operating in the medical wearable device market include:
• Dräger
• Fitbit Inc.
• Intelesens Ltd.
• Lifewatch AG
• Omron Corporation
• Polar Electro
• Philips Electronics
• Withings SAS
These wearable manufacturers will likely improve hardware in existing products and create sturdier devices within the next few years. Hardware and device ifrankmagliochettireport_wearable-medical-devicesnnovations may include larger and easier to read displays, extended battery life, waterproof hardware, and compatibility with GPS and other sensors included in a standard smart phone. Software innovations may include advanced monitoring systems and improved patient care software, such as breathing exercises and on-demand nutrition counseling.
The wearable market is expanding because the devices are autonomous, which makes them easy to use, and non-invasive. It is also growing because of its ability to help prevent and manage chronic diseases.

Source
https://www.mordorintelligence.com/industry-reports/global-wearable-medical-device-market-industry

Frank Magliochetti is Managing Partner for Parcae Capital.

  • North Andover, Massachusetts

This column of posts is directed at the Healthcare Industry.  Frank plans to release a new site dedicated to the industry.  He currently assists companies who are building, restructuring, transforming and resurrecting there business’s. An example of his client base are, Xenetic Biosciences , IPC Medical Corp, Just Fellowship Corp, Environmental Services Inc., Parsons Post House LLC, ClickStream Corporation as well as having a business talk radio show; The Business Architect on the URBN network.

frankmagliochetti_ParcaeCapital

2017 Trends in Cancer Care Drugs

2017 Trends in Cancer Care Drugs

Frank Magliochetti Report

Cancer drug development will continue to be a key focus area in 2017. While the number of new cancer frank-magliochettireport_2017_cancer-stopcases in the United States each year remains constant at about 1.7 million, the American Cancer Society says that the cancer death rate has plummeted 23 percent since the early 1990s. This is largely due to improved diagnostics, early detection, and new medications and treatments.
There has been extensive development of cancer medications in the past decade, and the development of oncology drugs will continue to be a key focus area in 2017. There are several important factors affecting cancer drug development in the upcoming year, including a large number of clinical trials already underway, the possibility of shortened regulatory approval time, and increases to consumer cost.

Cancer Drug Development

Extensive development of cancer medications is already underway, and much of this development will continue into 2017. New medicines, just launched within the past five years, now treat more than 20 types of tumors, according to a new report from IMS Institute for Healthcare Informatics. In fact, there were 70 new oncology treatments for more than 20 uses launched from 2011 to 2015. Further research of these new agents will likely result in approval for subsequent indications and provide therapeutic options to more patients.2017_cancertrends_frankmagliochetti
While there is substantial opportunity in the cancer drug industry, there will also be stiff competition in 2017. More than 500 companies are actively engaged in developing oncology drugs. Collectively, these companies are pursuing nearly 600 indications, primarily for non-small cell lung cancer, breast, prostate, ovarian and colorectal cancers.
This giant and diverse group of pharma companies has created a healthy pipeline of oncology drugs in clinical development. In fact, the pipeline of cancer drugs in clinical development has grown more than 60 percent over the past ten years.
Nearly 90 percent of these drugs are targeted agents, and the trend towards targeted agents will likely continue. There are more than 120 clinical development project underway for targeted agents to treat non-small cell lung cancer and melanoma, for example, and each features different mechanisms and combinations that promise new benefits.
It is taking less time for new cancer treatments to receive regulatory approval. The median time from patent filing to approval for cancer drugs in the U.S. dropped from 10.25 years in 2013 to 9.5 years in 2015. Initiatives such as the FDA Breakthrough Therapy designation expedite development and review of drugs that treat serious or life-threatening diseases or conditions.

Patient Costs may Rise

In campaign speeches, the new President-elect of the United States has promised changes to the Affordable Care Act, and these changes may increase patient costs. Average treatment costs for a year of cancer care for patients with commercial insurance plans rose 19 percent to $58,097 in 2014.  Cost increases in 2017 may depend on where the patient receives care. Outpatient services account for more than half of the total costs, according to the IMS report, and the average combined total cost of all  drugs used by the patient accounts for 28 percent of the total cost of care.
Average costs for administering cancer drugs are usually twice as high when patients receive treatment in hospital outpatient settings than when they receive care in physician offices. Higher costs for outpatient care increases patient cost responsibility. Coupons and other forms of assistance may offset the cost to consumers.

Source

http://onlinelibrary.wiley.com/doi/10.3322/caac.21332/abstract
https://morningconsult.com/wp-content/uploads/2016/06/IMS-Institute-Global-Oncology-Report-05.31.16.pdf

Frank Magliochetti is Managing Partner for Parcae Capital.

  • North Andover, Massachusetts

This column of posts is directed at the Healthcare Industry.  Frank plans to release a new site dedicated to the industry.  He currently assists companies who are building, restructuring, transforming and resurrecting there business’s. An example of his client base are, Xenetic Biosciences , IPC Medical Corp, Just Fellowship Corp, Environmental Services Inc., Parsons Post House LLC, ClickStream Corporation as well as having a business talk radio show; The Business Architect on the URBN network.

frankmagliochetti_ParcaeCapital

Pharmaceutical Trends for 2017: Biosimilars

Pharma Trends 2017:  Biosimilars

Frank Magliochetti Report

The FDA approved 56 new drugs in 2015 and, of these, 33 were specialty drugs and 23 were traditional. One was a biosimilar. Development, approval and acceptance of biosimilars may become an important trend in 2017.
The FDA is approving more specialty drugs than ever before and specialty medicines will likely face more competition in 2017. Increased FDA approval and frankmagliochetti-report-pharma-trends-biosimilarsdiscoveries of medications to treat orphan conditions and cancer will fuel competition. Biosimilars could overcome development hurdles and increase this competition even more.
Acceptance of biosimilars has been slow in the past. One of the reasons for the reluctance is that the development of biosimilars is different from that of generic drugs. Generic drugs for small molecules have a relative simple chemical structure that makes it easy to reproduce an identical chemical. It is more difficult to make a protein or peptide identical to the original biologic agent because of differences in the sugar residues attached to the protein, for example, or differences in the protein folding that make it unpredictable. This means that, even though a biosimilar has an identical peptide chain, it may not have an identical effect. These factors complicate the process of making biosimilars and increase the risk for problems.
Physician acceptance has been slow too but, as the cost of other medications rise, biosimilars will seem more attractive.
Approval of Biosimilars in 2015 and 2016
Biosimilars, which are products the FDA will approve with evidence that the medication up for approval is highly similar to an already-approved reference product, will probably continue to gain traction in 2017. The FDA has approved four biosimilars as of October 2016.
Zarxio is similar to Neupogen, according to an article published by Managed Healthcare Executive, except the biosimilar has a 15 percent lower list price. Both drugs treat low white blood cell counts associated with cancer and its treatment. The FDA approvedZarxio, made by Sandoz, in March 2015.
Inflectra is similar to Remicade to treat Crohn’s disease and ulcerative colitis. The FDA approved Inflectra in April 2016 but, due to litigation, the launch date is uncertain.
Erelzi, also made by Sandoz, is similar to Enbrel to treat arthritis. The FDA announced approval of Erelzi in August of 2016 and the expected launch date of biosimilar-frankmagliochetti-pharma-trends-2017February 2017 may be delayed.
Amjevita, by Amgen is similar to Humira and is for the treatment multiple inflammatory diseases. Amjevita became the fourth biosimilar drug to gain approval in September 2016. Launch date is set for March 2017 but may experience delays.
There are several biosimilars awaiting approval, including:
• Filgrastim by Grastofil, Apotex
• Pegfilgrastim by Apotex
• SB2 infliximab by Merck/Samsung Bioepis
• CHS‐1701 by Coherus Biosciences
• Epoetin alfa by Retacrit, Pfizer
The need for biosimilars will grow as the need for other drugs, especially cancer drugs and orphan drugs, increases. Doctors diagnose about 1.7 million cases of cancer each year, yet the death rate has fallen 23 percent since the early 1990s, partially due to new medications and treatments. The introduction of biosimilars could reduce cancer death rates even further.
Biosimilars may become one of the strongest trends in the pharmaceutical industry in upcoming years, as biosimilars have the potential to lower the cost for safe and effective treatments for a wider number of patients. Increased development of biosimilar cancer drugs is possible as some biopharmaceuticals lose patent protection.

Source
https://www.uspharmacist.com/article/record-number-of-fda-new-drug-approvals-in-2015
http://www.zarxio.com/index.jsp
http://managedhealthcareexecutive.modernmedicine.com/managed-healthcare-executive/news/five-specialty-pharmaceutical-trends-watch
http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm436648.htm
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm494227.htm
http://www.erelzi.com/
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm518639.htm
http://pi.amgen.com/united_states/AMJEVITA/AMJEVITA_mg.pdf
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm522243.htm

Frank Magliochetti is Managing Partner for Parcae Capital.

  • North Andover, Massachusetts

This column of posts is directed at the Healthcare Industry.  Frank plans to release a new site dedicated to the industry.  He currently assists companies who are building, restructuring, transforming and resurrecting there business’s. An example of his client base are, Xenetic Biosciences , IPC Medical Corp, Just Fellowship Corp, Environmental Services Inc., Parsons Post House LLC, ClickStream Corporation as well as having a business talk radio show; The Business Architect on the URBN network.

frankmagliochetti_ParcaeCapital

Genome Editing – Progressing Trend

The Rush for Genome Editing

Frank Magliochetti Report

The Rush for Genome Editing

Gene-editing technology has sparked a frenzy of competitors fueled to develop the first of what may be thousands of treatments for genetic disorders.

From science fiction of movies like Jurassic Park to the reality of GMO foods, the concept of customizing plants, animals and even human genomes has mesmerized our imagination and culture for decades. This obsession is not surprising considering the remarkable impact of genetic engineering on our lives, and the promise it may hold for our future.crispr-genome-editing-franlmagliochetti-report_northandoverma

Modifying the genes of an organism is no easy task. It’s not as simple as removing the parts you do not like with an eraser. It involves making changes at a molecular level that are both complex and challenging.

One concern among scientists is the modifications made in human germline cells – i.e. the sperm or the egg. These are genetic changes that would actually be passed on through generations and the fear is that there could be unexpected side effects. Couple that with the ethical concerns of people misusing this technology to intentionally modify the genome to make “designer babies” with enhanced characteristics. These are some real concerns that are causing scientists to pause and weigh the pros and cons of use of this technology.

More and more companies are racing to stay ahead of the trend and become the leaders in the field.

In Cambridge MA, Intellia Therapeutics Inc. has a 65,000 square foot build out underway, however, it is still planning to functioning while under construction.

Intellia is one of a trio of startups in the Cambridge area working locally in the biotech niche known as CRISPR-Cas9. The gene-editing technology was frank-magliochetti-report_intelliadiscovered just four years ago.

Drug development historically has been a slow process – it often takes more than a decade to bring a medicine from lab to marketplace. But that’s changing, thanks to new machines that can screen drug targets faster and an entrepreneurial environment that’s more akin to high-tech than Big Pharma.frankmagliochettireport_genome_editing

Intellia has high-profile collaboration deals with Swiss drug giant Novartis AG and Regeneron Pharmaceuticals Inc. of Tarrytown, N.Y. It raised $108 million in an initial public offering in May. Their scientists are working on gene-editing treatments for everything including the hepatitis B virus to a rare form of blindness. If all goes well, it could move its earliest drug candidates into clinical trials within 18 to 24 months.

Competitors for Intellia include Editas Medicine and Crispr Therapeutics Inc. both completed their own IPOs this year. There are more to come: all with the heightened interest of investors. These companies are in a race to develop the first treatment based on gene editing.

Genome editing is going to be a hot trend to watch in 2017 and for many years to come.

Frank Magliochetti is Managing Partner for Parcae Capital.

  • North Andover, Massachusetts

This column of posts is directed at the Healthcare Industry.  Frank plans to release a new site dedicated to the industry.  He currently assists companies who are building, restructuring, transforming and resurrecting there business’s. An example of his client base are, Xenetic Biosciences , IPC Medical Corp, Just Fellowship Corp, Environmental Services Inc., Parsons Post House LLC, ClickStream Corporation as well as having a business talk radio show; The Business Architect on the URBN network.

frankmagliochetti_ParcaeCapital

Genome Editing – CRISPR

Frank Magliochetti Report:   CRISPR

CRISPR trials just may be one the most important healthcare industry breakthroughs of this generation

Frank Magliochetti

Almost every year, a new disease is introduced in the world which affects the population of our country. It would be wrong to say that people living in rural areas may be more prone to catch diseases than those who are living in the city. The fact is that no matter where you live or how Frank-Magliochetti_crisprhard you try to protect yourself from the outside world, there are some in-house diseases that may catch up to you.

Once such disease that can strike anyone at any time is cancer which arises through our genetics.   A disease that in some cases runs down from generation to generation which may strike no matter what we may do to help prevent it.  It is something we all dread.

A study conducted on genetic based cancer diseases was conducted in the US and finally was granted access for testing on humans on June 21st.   The NIH (National Institute of Health) gave the green light to start testing the CRISPR-Cas9 trial on humans so that help from T Cells could be enlisted to protect the body.

To understand the trial, first, one needs to understand what exactly CRISPR-Cas9 is. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a drug derived from Streptococcus pyogenes, which enabled the researchers to make permanent mutations. This introduces double stranded healing breaks in cells to activate the repair pathways in a human body. They adapt immunity in certain archaea and bacteria, which allow organisms to invade and eliminate genetic material.

This disease was discovered in 1989 but until 2007 its symptoms were unknown. 2016 has brought new hope for people to live a healthy life. The trial will be funded by Sean Parker, a tech entrepreneur who has a $250 million dollar cancer treatment center; The Parker Institute for Cancer Immunotherapy.

There have been other trials conducted but the problem with them was that the T Cells, which were reintroduced to a person’s body were not that effective, however, they did kill the NY-ESO-1, the T Cells stopped proliferating and became less effective. crispr-magliochetti

There are many hospitals all over the world that are holding CRISPR trails. Some trials were started at the beginning of August while others are set to start in September.

Hospitals such as Massachusetts General Hospital located in Boston have been conducting tests on genome editing since 2013. This is one of the oldest hospitals in Boston and gets close to 100,000 patient visits per year. There are even chances that MGH affiliated laboratories will also conduct genome editing trials.

Many more hospitals based in Boston have announced that with proper funding, they will start genome editing trials in 2017. Since the trials are so expensive, scientists will pick patients who are immune to Cas9 enzyme.

The discovery and trials of CRISPR is one of the best advancements in medical history. Though the patients for the trial will be chosen in small numbers, people living in fear that their life may end after four or five years due to a genetic illness like Leukemia may now have new hope of living a healthy and happy life.

The content below was aggregated from a Boston Globe opinion piece by Jim Kozubek please click the link to head to the official site to read the rest of the post.

https://www.bostonglobe.com/ideas/2016/09/03/crispr-and-capitalists/uX8NuPsva5L2iNI2DCBArJ/story.html

CRISPR and the capitalists

CRISPER-CAS9 IS A method of manipulating DNA that is transforming medicine and science. It is both popular (“molecule of the year!”) and dangerous (researchers have received threats from GMO activists). It is also wildly lucrative.

The first clinical trial of these tiny molecular scissors may begin by the end of the year. Meanwhile, two camps, the Broad Institute — where I held affiliation for nearly three years — and University of California at Berkeley and researcher Emmanuelle Charpentier, are locked in a patent showdown that will play out in early 2017 with perhaps a billion dollars at stake.
Society treats science as a public trust by funding it through taxes, but perhaps it shouldn’t do so indefinitely. One of the subliminal things that the CRISPR-Cas9 legal showdown tells us is that academic-industry partnerships may one day be mature enough that science may begin to forgo its tax base.

In 1943, President Franklin D. Roosevelt directed his wartime chief of research, Vannevar Bush, to find a way to extend funding after the war. In a document with soaring language entitled “Science the Endless Frontier,” Bush laid out the argument for robust federal funding engines through the National Institutes of Health, the creation of the National Science Foundation, and what would become a briskly expanding network of research scientists throughout the United States.
Read More – CLICK HERE

Frank Magliochetti is Managing Partner for Parcae Capital.

  • North Andover, Massachusetts

This column of posts is directed at the Healthcare Industry.  Frank plans to release a new site dedicated to the industry.  He currently assists companies who are building, restructuring, transforming and resurrecting there business’s. An example of his client base are, Xenetic Biosciences , IPC Medical Corp, Just Fellowship Corp, Environmental Services Inc., Parsons Post House LLC, ClickStream Corporation as well as having a business talk radio show; The Business Architect on the URBN network.

frankmagliochetti_ParcaeCapital